Askelios Klinik München Gauting   Report issue

Academic/Hospital Phase 1 Phase 2
Founded: Germany

Organization Overview

First Clinical Trial
2016
NCT03227016
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Alternative names

Askelios Klinik München Gauting | Asklepios Fachkliniken München-Gauting, Thorakale Onkologie

Active Ingredients

Drugs in Phase 2 Trials (2)

durvalumab (imfinzi) (1 trial)

tremelimumab (Imjudo) (1 trial)

Drugs in Phase 1 Trials (2)

topotecan (hycamtin) (1 trial)

veliparib (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Lung Neoplasms (Phase 1)

Small Cell Lung Carcinoma (Phase 1)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 2
  • # of Trial APIs: 4